Emerging drugs for the treatment of knee osteoarthritis

Bibliography

• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol 2014;10:437-41
   PubMed Web of Science ®Google Scholar
• Dunlop DD, Manheim LM, Song J, Chang RW. Arthritis prevalence and activity limitations in older adults. Arthritis Rheum 2001;44:212-21
   PubMed Web of Science ®Google Scholar
• Hunter DJ. Lower extremity osteoarthritis management needs a paradigm shift. Br J Sports Med 2011;45:283-8
   PubMed Web of Science ®Google Scholar
• Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54:226-9
   PubMed Web of Science ®Google Scholar
• Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007;213:626-34
   PubMed Web of Science ®Google Scholar
• Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis 2013;5:77-94
   PubMedGoogle Scholar
• Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011;23:471-8
   PubMed Web of Science ®Google Scholar
• Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012;51:249-57
   PubMed Web of Science ®Google Scholar
• Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010;6:625-35
   PubMed Web of Science ®Google Scholar
• Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012;64:1697-707
   PubMed Web of Science ®Google Scholar
• Neogi T. Clinical significance of bone changes in osteoarthritis. Ther Adv Musculoskelet Dis 2012;4:259-67
   PubMedGoogle Scholar
• Loeser RF. Aging and osteoarthritis. Curr Opin Rheumatol 2011;23:492-6
   PubMed Web of Science ®Google Scholar
• Loeser RF. Aging processes and the development of osteoarthritis. Curr Opin Rheumatol 2013;25:108-13
   PubMed Web of Science ®Google Scholar
• Wood JN. Nerve growth factor and pain. N Engl J Med 2010;363:1572-3
   PubMed Web of Science ®Google Scholar
• Hill CL, Gale DG, Chaisson CE, et al. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol 2001;28:1330-7
   PubMed Web of Science ®Google Scholar
• Hill CL, Hunter DJ, Niu J, et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis 2007;66:1599-603
   PubMed Web of Science ®Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363-88
   PubMed Web of Science ®Google Scholar
• Losina E, Paltiel AD, Weinstein AM, et al. Lifetime medical costs of knee osteoarthritis management in the United States: Impact of extending indications for total knee arthroplasty. Arthritis Care Res 2015;67(2):203-15
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky AB, Leslie DL, et al. Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain. Pain Pract 2012;12:457-68
   PubMed Web of Science ®Google Scholar
• Bourne RB, Chesworth BM, Davis AM, et al. Patient satisfaction after total knee arthroplasty: who is satisfied and who is not? Clin Orthop Relat Res 2010;468:57-63
   PubMed Web of Science ®Google Scholar
• Beswick AD, Wylde V, Gooberman-Hill R, et al. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open 2012;2:e000435
   PubMed Web of Science ®Google Scholar
• Mitchell HL, Hurley MV. Management of chronic knee pain: a survey of patient preferences and treatment received. BMC Musculoskelet Disord 2008;9:123
   PubMed Web of Science ®Google Scholar
• Craig DG, Bates CM, Davidson JS, et al. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol 2012;73:285-94
   PubMed Web of Science ®Google Scholar
• Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Le Bars M, Schmidely N, Dougados M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 2004;63:923-30
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006;119:448 e27-36
   PubMed Web of Science ®Google Scholar
• Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. Agency for Healthcare Research and Quality: Rockville (MD): 2011
   Google Scholar
• Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009;143:238-45
   PubMed Web of Science ®Google Scholar
• Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002-12
   PubMed Web of Science ®Google Scholar
• Nuesch E, Rutjes AW, Husni E, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009(4):CD003115
   PubMedGoogle Scholar
• Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010;170:1968-76
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6
   PubMed Web of Science ®Google Scholar
• Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370-7
   PubMed Web of Science ®Google Scholar
• Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41
   PubMed Web of Science ®Google Scholar
• Frakes EP, Risser RC, Ball TD, et al. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:2361-72
   PubMed Web of Science ®Google Scholar
• Mobasheri A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr Rheumatol Rep 2013;15:364
   PubMed Web of Science ®Google Scholar
• Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780-5
   PubMed Web of Science ®Google Scholar
• Nho SJ, Kymes SM, Callaghan JJ, Felson DT. The burden of hip osteoarthritis in the United States: epidemiologic and economic considerations. J Am Acad Orthop Surg 2013;21(Suppl 1):S1-6
   PubMed Web of Science ®Google Scholar
• Losina E, Daigle ME, Suter LG, et al. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis Cartilage 2013;21:655-67
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Cooper C, Arden N, et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013;43:303-13
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Janagap C, et al. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med 2008;50:998-1005
   PubMed Web of Science ®Google Scholar
• Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009;15:S230-5
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Balint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9:R109
   PubMed Web of Science ®Google Scholar
• Hunter DJ. Pharmacologic therapy for osteoarthritis–the era of disease modification. Nat Rev Rheumatol 2011;7:13-22
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. 2014. Available from: https://clinicaltrials.gov [Last accessed 8 January 2015]
   Google Scholar
• Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363:1521-31
   PubMed Web of Science ®Google Scholar
• Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013;65:1795-803
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Kivitz AJ, Ervin JE, et al. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain 2014;155:1245-52
   PubMed Web of Science ®Google Scholar
• Burnstock G. Introduction to purinergic signalling in the brain. Adv Exp Med Biol 2013;986:1-12
   PubMed Web of Science ®Google Scholar
• Burnstock G. Purinergic receptors and pain. Curr Pharm Des 2009;15:1717-35
   PubMed Web of Science ®Google Scholar
• Honore P, Kage K, Mikusa J, et al. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 2002;99:11-19
   PubMed Web of Science ®Google Scholar
• Dray A, Read SJ. Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther 2007;9:212
   PubMed Web of Science ®Google Scholar
• Rao PP, Mohamed T. Current and emerging “at-site” pain medications: a review. J Pain Res 2011;4:279-86
   PubMedGoogle Scholar
• McGaraughty S, Jarvis MF. Antinociceptive properties of a non-nucleotide P2X3/P2X2/3 receptor antagonist. Drug News Perspect 2005;18:501-7
   PubMed Web of Science ®Google Scholar
• Gever JR, Soto R, Henningsen RA, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol 2010;160:1387-98
   PubMed Web of Science ®Google Scholar
• Youn Choi H, Jin SJ, Jung JA, et al. Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. Clin Ther 2014;36:115-25
   PubMed Web of Science ®Google Scholar
• Skarke C, Alamuddin N, Lawson JA, et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther 2012;91:986-93
   PubMed Web of Science ®Google Scholar
• Schmidt WK, Lehnhardt J, Hettwer O, et al. CG100649, a tissue-specific dual inhibitor of COX-2 and carbonic anhydrase: phase2A clinical trial in knee and hip osteoarthritis. Osteoarthritis Cartilage 2009;17:S173
   Google Scholar
• Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 2010;18:1441-7
   PubMed Web of Science ®Google Scholar
• Kidd BL, Photiou A, Inglis JJ. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp 2004;260:122-33. discussion 33-8, 277-9
   PubMedGoogle Scholar
• Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 2012;71:891-8
   PubMed Web of Science ®Google Scholar
• Chevalier X, Ravaud P, Maheu E, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2014;10.1136/annrheumdis-2014-205348
   PubMedGoogle Scholar
• Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009;29:961-5
   PubMed Web of Science ®Google Scholar
• Urech DM, Feige U, Ewert S, et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis 2010;69:443-9
   PubMed Web of Science ®Google Scholar
• Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23
   PubMed Web of Science ®Google Scholar
• Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009;61:344-52
   PubMed Web of Science ®Google Scholar
• Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011;13:R125
   PubMed Web of Science ®Google Scholar
• Wang SX, Medema JK, Kosloski MP, et al. Interleukin-1 dual variable-domain immunoglobulin reduces multiple inflammatory markers in knee osteoarthritis patients. Ann Rheum Dis 2014;73:756
   PubMed Web of Science ®Google Scholar
• Loeser RF, Erickson EA, Long DL. Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol 2008;20:581-6
   PubMed Web of Science ®Google Scholar
• Starkman BG, Cravero JD, Delcarlo M, Loeser RF. IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. Biochem J 2005;389:723-9
   PubMed Web of Science ®Google Scholar
• Chun JS. Expression, activity, and regulation of MAP kinases in cultured chondrocytes. Methods Mol Med 2004;100:291-306
   PubMedGoogle Scholar
• Kim SJ, Ju JW, Oh CD, et al. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J Biol Chem 2002;277:1332-9
   PubMed Web of Science ®Google Scholar
• Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81
   PubMed Web of Science ®Google Scholar
• Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007;28:286-95
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ. New pharmacologic approaches in the management of osteoarthritis. Arthritis Care Res (Hoboken) 2010;62:1174-80
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Lascau-Coman V, Jovanovic D, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999;26:2002-14
   PubMed Web of Science ®Google Scholar
• Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs 2011;16:479-91
   PubMed Web of Science ®Google Scholar
• Hellio le Graverand MP, Clemmer RS, Redifer P, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013;72:187-95
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol 2001;22:211-16
   PubMed Web of Science ®Google Scholar
• Jaakkola K, Nikula T, Holopainen R, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 2000;157:463-71
   PubMed Web of Science ®Google Scholar
• Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 2008;28:18-26
   PubMed Web of Science ®Google Scholar
• Marttila-Ichihara F, Smith DJ, Stolen C, et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 2006;54:2852-62
   PubMed Web of Science ®Google Scholar
• Brechter AB, Lerner UH. Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. Arthritis Rheum 2007;56:910-23
   PubMed Web of Science ®Google Scholar
• Meini S, Cucchi P, Catalani C, et al. Bradykinin and B(2) receptor antagonism in rat and human articular chondrocytes. Br J Pharmacol 2011;162:611-22
   PubMed Web of Science ®Google Scholar
• Bellucci F, Cucchi P, Catalani C, et al. Novel effects mediated by bradykinin and pharmacological characterization of bradykinin B2 receptor antagonism in human synovial fibroblasts. Br J Pharmacol 2009;158:1996-2004
   PubMed Web of Science ®Google Scholar
• Terzuoli E, Meini S, Cucchi P, et al. Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation. PLoS ONE 2014;9:e84358
   PubMed Web of Science ®Google Scholar
• Song IH, Althoff CE, Hermann KG, et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann Rheum Dis 2009;68:75-83
   PubMed Web of Science ®Google Scholar
• Meini S, Maggi CA. Knee osteoarthritis: a role for bradykinin? Inflamm Res 2008;57:351-61
   PubMed Web of Science ®Google Scholar
• Griffith DL, Keck PC, Sampath TK, et al. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc Natl Acad Sci USA 1996;93:878-83
   PubMed Web of Science ®Google Scholar
• Elshaier AM, Hakimiyan AA, Rappoport L, et al. Effect of interleukin-1beta on osteogenic protein 1-induced signaling in adult human articular chondrocytes. Arthritis Rheum 2009;60:143-54
   PubMed Web of Science ®Google Scholar
• Merrihew C, Kumar B, Heretis K, et al. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. J Orthop Res 2003;21:899-907
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010;11:232
   PubMed Web of Science ®Google Scholar
• Moore EE, Bendele AM, Thompson DL, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005;13:623-31
   PubMed Web of Science ®Google Scholar
• Ellman MB, An HS, Muddasani P, Im HJ. Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis. Gene 2008;420:82-9
   PubMed Web of Science ®Google Scholar
• Sandell LJ, Xing X, Franz C, et al. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage 2008;16:1560-71
   PubMed Web of Science ®Google Scholar
• Mastbergen SC, Saris DB, Lafeber FP. Functional articular cartilage repair: here, near, or is the best approach not yet clear? Nat Rev Rheumatol 2013;9:277-90
   PubMed Web of Science ®Google Scholar
• Lohmander LS, Hellot S, Dreher D, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014;66:1820-31
   PubMed Web of Science ®Google Scholar
• Staines KA, Mackenzie NC, Clarkin CE, et al. MEPE is a novel regulator of growth plate cartilage mineralization. Bone 2012;51:418-30
   PubMed Web of Science ®Google Scholar
• Sprowson AP, McCaskie AW, Birch MA. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. J Orthop Res 2008;26:1256-62
   PubMed Web of Science ®Google Scholar
• Hayashibara T, Hiraga T, Yi B, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 2004;19:455-62
   PubMed Web of Science ®Google Scholar
• Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 2013;9:721-30
   PubMed Web of Science ®Google Scholar
• Andia I, Sanchez M, Maffulli N. Tendon healing and platelet-rich plasma therapies. Expert Opin Biol Ther 2010;10:1415-26
   PubMed Web of Science ®Google Scholar
• Gomez R, Villalvilla A, Largo R, et al. TLR4 signalling in osteoarthritis-finding targets for candidate DMOADs. Nat Rev Rheumatol 2015;11:159-70
   PubMed Web of Science ®Google Scholar
• Kim HA, Cho ML, Choi HY, et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006;54:2152-63
   PubMed Web of Science ®Google Scholar
• Marcu KB, Otero M, Olivotto E, et al. NF-kappaB signaling: multiple angles to target OA. Curr Drug Targets 2010;11:599-613
   PubMed Web of Science ®Google Scholar
• Bendinelli P, Matteucci E, Dogliotti G, et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF. J Cell Physiol 2010;225:757-66
   PubMed Web of Science ®Google Scholar
• Laudy AB, Bakker EW, Rekers M, Moen MH. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med 2014;10.1136/bjsports-2014-094036
   PubMed Web of Science ®Google Scholar
• Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord 2012;13:229
   PubMed Web of Science ®Google Scholar
• Sanchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy 2012;28:1070-8
   PubMed Web of Science ®Google Scholar
• Cerza F, Carni S, Carcangiu A, et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med 2012;40:2822-7
   PubMed Web of Science ®Google Scholar
• Vaquerizo V, Plasencia MA, Arribas I, et al. Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. Arthroscopy 2013;29:1635-43
   PubMed Web of Science ®Google Scholar
• Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy 2011;27:1490-501
   PubMed Web of Science ®Google Scholar
• Filardo G, Kon E, Pereira Ruiz MT, et al. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc 2012;20:2082-91
   PubMed Web of Science ®Google Scholar
• Say F, Gurler D, Yener K, et al. Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. Acta Chir Orthop Traumatol Cech 2013;80:278-83
   PubMed Web of Science ®Google Scholar
• Spakova T, Rosocha J, Lacko M, et al. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 2012;91:411-17
   PubMed Web of Science ®Google Scholar
• Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013;41:356-64
   PubMed Web of Science ®Google Scholar
• Scharstuhl A, Glansbeek HL, van Beuningen HM, et al. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol 2002;169:507-14
   PubMed Web of Science ®Google Scholar
• Shen J, Li J, Wang B, et al. Deletion of the transforming growth factor beta receptor type II gene in articular chondrocytes leads to a progressive osteoarthritis-like phenotype in mice. Arthritis Rheum 2013;65:3107-19
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-17
   PubMed Web of Science ®Google Scholar
• Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol 2013;9:584-94
   PubMed Web of Science ®Google Scholar
• Gupta PK, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res Ther 2012;3:25
   PubMed Web of Science ®Google Scholar
• van der Kraan PM, Goumans MJ, Blaney Davidson E, ten Dijke P. Age-dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue Res 2012;347:257-65
   PubMed Web of Science ®Google Scholar
• Lee CH, Cook JL, Mendelson A, et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 2010;376:440-8
   PubMed Web of Science ®Google Scholar
• Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-74
   PubMed Web of Science ®Google Scholar
• Sondergaard BC, Wulf H, Henriksen K, et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006;14:759-68
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Sondergaard BC, Arnold M, Christiansen C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci 2007;1117:181-95
   PubMed Web of Science ®Google Scholar
• Esenyel M, Icagasioglu A, Esenyel CZ. Effects of calcitonin on knee osteoarthritis and quality of life. Rheumatol Int 2013;33:423-7
   PubMed Web of Science ®Google Scholar
• Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54:3205-11
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Alexandersen P, John MR, et al. Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2011;19:S35
   Web of Science ®Google Scholar
• Bingham COIII, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507
   PubMed Web of Science ®Google Scholar
• Walsh DA, Chapman V. Bisphosphonates for osteoarthritis. Arthritis Res Ther 2011;13:128
   PubMed Web of Science ®Google Scholar
• Saag KG. Bisphosphonates for osteoarthritis prevention: “Holy Grail” or not? Ann Rheum Dis 2008;67:1358-9
   PubMed Web of Science ®Google Scholar
• Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33
   PubMed Web of Science ®Google Scholar
• Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012;71:1322-8
   PubMed Web of Science ®Google Scholar
• Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013;72:179-86
   PubMed Web of Science ®Google Scholar
• Bodick N, Luflin J, Willwerth C, et al. Safety and efficacy of FX006 in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2014;22:S376-7
   Web of Science ®Google Scholar
• Petrella RJ, Eamans P, Alleyne J, Maroney M. A prospective, multi-center, randomized, double-blind feasibility study to evaluate the safety and performance of hydros joint therapy and Hydros-TA joint therapy for management of pain associated with osteoarthritis in the knee. Osteoarthritis Cartilage 2012;20:S172-3
   PubMed Web of Science ®Google Scholar